Work

Targeting mitochondrial Kv1.3 enables precise autoreactive T cell therapy for multiple sclerosis

Year: 2025

Type: article

Abstract: Multiple sclerosis (MS), a chronic autoimmune disorder, is characterized by the infiltration of autoreactive T cells into the central nervous system (CNS), leading to myelin destruction and neurological deficits. Current therapies often lack specificity, resulting in broad immunosuppression and potential side effects. In this issue of EMBO Molecular Medicine, Angi, Varanita and colleagues (Angi et al, 2025) identify a novel therapeutic strategy in targeting the mitochondrial Kv1.3 channel in autoreactive T cells, offering a more selective approach to mitigate MS-like pathology. Pluchino and Willis discuss a study by Szabo et al (in this issue of EMBO Mol Med) that reveals a novel therapy to treat multiple sclerosis by targeting the mitochondrial Kv1.3 channel in autoreactive T cells.

Source: EMBO Molecular Medicine

DOI: 10.1038/s44321-025-00306-3

Authors: Stefano Pluchino, Cory M Willis

Institutions: University of Cambridge, NIHR Cambridge Biomedical Research Centre

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $7,990